A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment

Trial Profile

A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TANIA
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results (n=210) of an exploratory analysis of prognostic tissue biomarkers were presented at the 41st European Society for Medical Oncology Congress
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top